Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Observation of Cardiac Safety With Proteasome Inhibition

Next Previous
Trial Profile

Prospective Observation of Cardiac Safety With Proteasome Inhibition

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 24 Mar 2023 Results assessing proteomics analysis of Carfilzomib (Cfz) related heart failure in multiple myeloma patients from prospective study of cardiac events during proteasome inhibitor therapy, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
  • 18 Mar 2022 Results (n=57)performing untargeted metabolomics on the baseline plasma samples in MM patients receiving CFZ to build a predictive model for CFZ-CVAE based on metabolomic signals, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 10 Sep 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top